DavidPSchenkeinMD

Oncology • Boston, MA

Hematologic Oncology

Physician

Join to view full profile

Dr. Schenkein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schenkein's full profile

Already have an account?

Office
800 Washington St
Tufts Medical Center Box 836
Boston, MA 02111
Phone+1 617-636-7652

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1989
Tufts Medical CenterResidency, Internal Medicine, 1983 - 1986
SUNY Upstate Medical UniversityClass of 1983

Certifications & Licensure

MA State Medical License 1985 - 2026
CA State Medical License 2006 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1997 Jul 01
Completed
Phase 3

Publications & Presentations

PubMed

2 citations
US immigration order strikes against biotech
Jeremy M Levin, Steven H Holtzman, John M. Maraganore, Paul Hastings, Ron Cohen
Nature Biotechnology. 2017-03-07
103 citations
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.
Andrew Kernytsky, Fang Wang, Erica Hansen, Stefanie Schalm, Kimberly Straley
Blood. 2015-01-08
59 citations
Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate
Amir T. Fathi, Hossein Sadrzadeh, Amy Comander, Michaela J. Higgins, Aditya Bardia
The Oncologist. 2014-06-01

Press Mentions

Luba Greenwood Takes the Helm at Kojin Therapeutics, Steering an All-Female C-suite; Alexion R&D Chief Packs up for Change of Scenery at VC FirmOctober 15th, 2021
Bluebird Bio to Separate Oncology Business into Independent CompanyJanuary 11th, 2021
RESILIENCE Launches to Change the Future of Medicine Through Manufacturing InnovationNovember 23rd, 2020
Join now to see all